The Pharmacy Times® Diabetes resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Examining several biomarkers to look for biological explanations for these results, the research team found key mechanisms, including insulin resistance, body mass index (BMI), lipoprotein metabolism, and inflammation, according to the study authors.
Results from 2 pooled post-hoc analyses of phase 3 ORION-9, -10, and -11 trials evaluating inclisiran demonstrated the treatment was well-tolerated and effective.
Biological processes may be limiting the ability of insulin to adapt to obesity, rendering most people vulnerable to type 2 diabetes.
Through Project IMPACT: Diabetes Prevention, the APhA Foundation has built the infrastructure that allows the National DPP to be offered using an innovative service model.
The drug combination of dapagliflozin and exenatide continues to stay effective without a loss of effect after 2 years of continual use in patients with type 2 diabetes (T2D), according to researchers at Thomas Jefferson University.
Further research is essential in order to determine the relationship between diabetes and COVID-19 and what impact glucose-lowering drugs may have.
For patients with type 1 and type 2 diabetes, these computerized devices offer a break from conventional daily injections, while allowing patients to still reach and maintain their A1c levels and blood sugar targets.
Dogs and Cats have different blood make-ups and need a specifically calibrated device for glucose monitoring to manage diabetes.
The research found that obese patients with diabetes were significantly less likely to develop pancreatic cancer if they had undergone bariatric surgery, with the majority of the patients in the study being female.
Insulin prices are 8 times higher in the United States than 32 other high-income countries combined.
Integrating specialty pharmacy staff into oncology, neurology, rheumatology, and other specialty clinics within their health systems is a growing trend with a range of beneficial outcomes.
The Rare and Atypical Diabetes Network (RADIANT) plans to screen approximately 2000 people with unknown or atypical forms of diabetes that do not fit the common features of type 1 diabetes (T1D) and type 2 diabetes (T2D).